Primary contact

Tempus is building the world's largest library of molecular and clinical data and an operating system to make that data accessible and useful. It uses optical character recognition, advanced image recognition, natural language processing, and manual curation to structure phenotypic, therapeutic and outcomes data — including clinical records, pathology images and radiology scans — to uncover phenotypic, therapeutic and outcomes data for every patient. Also, the company's genomic tests analyze DNA and RNA data to understand a patient's tumor at a molecular level and uncover more personalized treatment options. Tempus' analytical and machine learning platform then analyzes all of these clinical and molecular data points to enable physicians to deliver personalized cancer care for patients for more impactful outcomes. The company provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Tempus' goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data.
Primary contact

Funding 💰

Total $1.3B
Select investors Google, Baillie Gifford, New Enterprise Associates, T. Rowe Price, Revolution, Novo Holdings
Last update: October 21, 2022